The main business activity of Trigon Property Development AS is real estate development. As at 31.03.2026, AS Trigon Property Development owned one development project with an area of 13.2 hectares in the City of Pärnu, Estonia. A commercial, industrial and logistics park is planned on this area. The Company’s objective is to find companies willing to bring their business activities (industry, logistics) to the development project area of AS Trigon Property Development in Pärnu, which would add value to the land plots owned by the Company. As the main purpose of the company is to sell existing land plots, investment property was recognized as inventories. Condensed statement of financial position as of 31 March 2026 delivered by the present announcement completely reflects the assets, liabilities and equity capital of AS Trigon Property...

Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains Company Held Approximately 2.15 Billion SKY Tokens at March 31, 2026 and Approximately 2.26 Billion SKY Tokens at May 14, 2026 Key HighlightsOperating income of $22.3 million for the first quarter of 2026, compared with an operating loss of $3.3 million for the first quarter of 2025.GAAP net income of $552.4 million for the first quarter of 2026, including a net non-cash gain of approximately $535.0 million from warrant-related effects during the period.Staking revenue of $2.5 million, representing 35,386,649 SKY tokens earned during the first quarter of 2026.Unrealized gain on digital assets of $22.7 million recognized during the first quarter of 2026.Cash and cash equivalents...

Expansion of Israel Electric Corporation IC Drone Contract Expected to Generate Over $1 Million in 2026 Revenue Launch of AEROTRACE™ AI-Powered Aerial Intelligence Platform; Bird of Prey Defense Drone Collaboration with Elbit Continues to Advance as Global Defense Spending on Drone Tech Rises Subsequent to Quarter End, Company Completed Approximately $9.2 Million Underwritten Public Offering and Uplisting on the Nasdaq Capital Market FT. LAUDERDALE, FL, May 20, 2026 (GLOBE NEWSWIRE) — Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) (“Duke Robotics” or the “Company”), a leader in advanced robotics and drone-based solutions for civilian and defense markets, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. Yossef Balucka, Chief Executive Officer of Duke Robotics, commented:...

MAYFIELD VILLAGE, OHIO, May 20, 2026 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended April 30, 2026:  April(millions, except per share amounts and ratios; unaudited)   2026       2025     ChangeNet premiums written $ 7,278     $ 6,837     6 %Net premiums earned $ 7,112     $ 6,641     7 %Net income $ 1,087     $ 986     10 %Per share available to common shareholders $ 1.86     $ 1.68     11 %Total pretax net realized gains (losses) on securities $ 402     $ (3 )   NM  Combined ratio   90.2       84.9     5.3 pts.Average diluted equivalent common shares   585.3       587.7     0 %NM = Not Meaningful                April 30,(thousands; unaudited) 2026   2025   % ChangePolicies in Force          Personal Lines          Agency...

ATHENS, Greece, May 20, 2026 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today its results for the three-month period ended March 31, 2026. First Quarter 2026 Highlights:Total net revenues of $12.8 million.Net income attributable to controlling shareholders, of $0.26 million or $0.09 earnings per share attributable to controlling shareholders basic and diluted.Adjusted net income1 attributable to controlling shareholders for the quarter of $0.33 million or $0.12 earnings per share attributable to controlling shareholders basic and diluted, which represents the net income attributable to controlling shareholders excluding the unrealized loss on derivatives.Adjusted EBITDA1 was $4.9...

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) fully enrolled with topline data expected in the second half of calendar year 2026 All other clinical development timelines remain on track for IMVT-1402, including potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren’s disease (SjD) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m....

BRANFORD, Conn., May 20, 2026 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) (“Sachem” or the “Company”), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced its financial results for the quarter ended March 31, 2026. John Villano, CPA, Sachem’s Chief Executive Officer, commented, “During the first quarter, we remained focused on disciplined capital and liquidity management, continuing the strategic priorities established last year. We made meaningful progress resolving legacy loan issues and protecting invested capital, positioning the Company for improved operating performance and future growth. Subsequent to quarter end, we announced a transformational combination transaction with Industrial...

SHANGHAI, China, May 20, 2026 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsNet revenue increased by 23.6% year-over-year (“Y-o-Y”) to RMB3,367.1 million (US$488.1 million) in the first quarter of 2026 (1Q2025: RMB2,723.2 million). Net revenue excluding some one-time items was RMB2,938.0 million (US$425.9 million), an increase of 7.9% Y-o-Y. Net income increased by 247.1% Y-o-Y to RMB2,652.1 million (US$384.5 million) in the first quarter of 2026 (1Q2025: RMB764.1 million). Net income margin was 78.8% in the first quarter of 2026 (1Q2025: 28.1%). Adjusted EBITDA...

Key First Quarter reported data points:Revenue of $12.2 million, -19.0% vs. Q1 2025 GAAP net income from continuing operations of $343 thousand vs. $254 thousand in Q1 2025 GAAP net income from continuing operations per fully diluted share of $0.006 vs. $0.005 in Q1 2025 Non-GAAP adjusted EBITDA of $441 thousand vs. $593 thousand in Q1 2025BROADVIEW, Ill., May 20, 2026 (GLOBE NEWSWIRE) — Innovative Food Holdings, Inc. (OTCQB: IVFH) (“IVFH,” the “Company,” “we,” “our” or “us”), a national seller of gourmet specialty foods to professional chefs, today reported financial results for the quarter ended March 31, 2026. For the first quarter of 2026, revenue was $12.2 million compared with $15.0 million in the prior-year period. The revenue decline reflected known transition-related and competitive headwinds across Digital Channels,...

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline Phase 3 data for brepocitinib in non-infectious uveitis (NIU) is expected in the second half of calendar year 2026IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus...